Next Level OAB Management: Emerging Strategies and Treatments.
Sponsored by Pierre Fabre
The symposium will focus on the latest innovations in Overactive Bladder (OAB) management, exploring both current unmet needs and future directions. Discussions will encompass the pathophysiology, diagnosis, and treatment options available in 2024, addressing patient expectations and the evolving role of selective ß3 adrenoreceptors. Notably, the symposium will feature phase 3 clinical data on a novel selective ß3 agonist, with practical insights through clinical case discussions. Distinguished speakers will guide these discussions, ensuring a comprehensive understanding of cutting-edge strategies in OAB management. This session aims to gain practical knowledge that can be applied in clinical practice and foster interactive discussions, allowing attendees to address key topics with experts. It is ideal for healthcare professionals looking to stay updated on the latest advancements in OAB therapy and improve patient outcomes through innovative treatments.
| Schedule |
|
| 1:15 - 1:17pm |
Introduction
Prof. John Heesakkers |
| 1:17 - 1:32pm |
OAB Diagnosis & Treatment in 2024: Are There Still Unmet Needs?
Prof. Enrico Finazzi Agrò |
| 1:50 - 1:47pm |
How Can We Better Address Patient Expectations?
Dr. Bárbara Padilla |
| 1:47 - 2:02pm |
ß3 Adrenoreceptor and the Bladder: The Role of Subtype Selectivity
Prof. Martin Michel |
| 2:02 - 2:22pm |
Phase 3 Clinical Data of a New Selective ß3 Agonist
Dr. David Staskin |
| 2:22 - 2:37pm |
Clinical Cases
Prof. Christian Gratzke |
| 2:37 - 2:42pm |
Discussion - Q&A |
| 2:42 - 2:45pm |
Conclusion
Prof. John Heesakkers |
Speaker/Moderator Information
John Heesakkers studied Medicine at the Radboud University of Nijmegen. In 1987 he received his MBA at the Rotterdam School of Management. He started his training in Urology in 1993 at the University Hospital Maastricht. From 2000 to 2020 he was a full-time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He headed the Unit of Functional Urology and Neurourology in the Radboudumc.
Since 2020 he is Professor at Maastricht University and as Head of the Department of Urology of the Maastricht UMC, the Netherlands. He chaired the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology from 2007 until 2022. He is a member of the EAU, ICS and SIU. Since September 2022 is the General Secretary of the ICS and since 2021 he is the Secretary General of the Association of Academic European Urologists. He is a faculty member of the European School of Urology and of the Scientific Congress Office of the EAU and is reviewer of several major urologic scientific journals. He is the author of approximately 200 peer-reviewed papers, book-chapters and books on urological topics.
Since becoming a Urology specialist in 1998, Enrico Finazzi Agro has held positions as Associate Professor at the University of Roma "Tor Vergata" since 2005, advancing to Full Professor in March 2022. He has chaired the Urology Department at Policlinico Tor Vergata University Hospital since 2018, following a decade-long tenure as head of the functional urology unit from 2008 to 2018. He directed the Urology training program at the University of Roma "Tor Vergata" from November 2016 to October 2022.
His research interests span neuro-urology, urodynamics, urinary incontinence and cervico-urethral obstruction diagnostics and treatments, prostate cancer, and andrology. With 163 papers indexed on PubMed (February 2024) and 184 publications on Scopus, he holds an H-index of 34 (February 2024). He has served as a reviewer for top journals and holds editorial roles at Neurourol Urodyn and International Urogynecology Journal and Continence.
He has been A member of SIU and SIUD since 1993, he also contributes to EAU and ICS, having served as president of the Italian Urodynamics Society (2015-2018) and trustee of the International Continence Society since November 2020. He plays a significant role in the EAU Section of Functional Urology, where he was elected chairman in February 2024
Bárbara Padilla-Fernández (La Laguna, Tenerife, Spain, 1983) received her medical degree from the University of Valladolid (Castilla y León, Spain) in 2007. She was Resident of Urology at the University Hospital of Salamanca between 2008-2013. She works at Hospital Universitario de Canarias (Tenerife, Canary Islands, Spain). She is associate professor of Urology at the Universidad de La Laguna (Tenerife, Canary Islands, Spain). Her main clinical and research interest is focused on Neuro-Urology, Functional and Female Urology. Currently belongs to the executive board of the SINUG and she is a member of the panel of the EAU Guidelines on Neurourology. She is author and co-author of several peer-review manuscripts and book chapters. She has experience in giving lectures in Spanish and English language in both national and international meetings.
Martin Michel completed his medical studies in Essen and Vienna, earning his medical degree in 1985. He obtained his doctorate from the University of Essen in 1987 based on research conducted at the Dept. of Biochemistry. He became board-certified as a pharmacologist in 1990 and as a clinical pharmacologist in 1997.
From 1993 to 2002, he headed the Nephrology and Hypertension Research Laboratory at the University of Essen. He then served as professor and head of the Department of Pharmacology & Pharmacotherapy at the University of Amsterdam and later as Global Head of Product and Pipeline Scientific Support at Boehringer Ingelheim. Currently, he holds the position of Professor of Pharmacology at Johannes Gutenberg University in Mainz, Germany.
He is actively involved in numerous national and international pharmacological and urological societies. He has served as past Editor-in-Chief of Naunyn-Schmiedeberg’s Archives of Pharmacology and sits on the editorial boards of prestigious journals such as Molecular Pharmacology. With over 300 articles published in peer-reviewed journals, his notable accolade includes election into the Academia Europaea, the European academy of sciences. He’s research focuses on urogenital and cardiovascular pharmacology and physiology, encompassing molecular pharmacology through to clinical trials.
David Staskin practices in Boston, MA at Tufts University School of Medicine, St. Elizabeth's Medical Center-Steward Health. He has also served as a member:
HHS Incontinence Guidelines, ICI Guidelines for Incontinence Initial Evaluation x2 Conservative Therapies x1, AUA Guidelines: “Surgical Management of Stress Urinary Incontinence.” Society for Urodynamics and Female Urology (past Board of Directors), American Urogynecological Society (past Board of Directors) and American Association Clinical Urologists / UROPAC (past Board of Directors)
He also serves on the follow journals as a reviewer or editor like International Urogynecology. He has published extensively (> 145 articles) in the areas of female urology, male voiding dysfunction, BPH and LUTS, neuro-urology, and urodynamics. He is an editor of the textbooks - Textbook of Female Urology and Urogynecology 4th edition. (eds. Cardozo and Staskin) – Atlas of Bladder Diseases (ed. Staskin) and Interstitial Cystitis (eds. Hanno, Staskin, Wein, Krane) – Bladder Pain Syndrome – IC (eds. Hanno, Staskin et.al.)
He has lectured nationally and internationally on topics related to voiding dysfunction in female and male patients. He has chaired multiple symposia on uropharmacology at the ICS meetings, AUA, and EAU.
He holds multiple device patents (67) and is the inventor of several mid-urethral slings and pelvic prolapse products.
Christian Gratzke is Professor and Chair at the Department of Urology at the Albert-Ludwigs-University in Freiburg, Germany. After Medical School at the LMU Munich and University of Vienna, he completed a research fellowship at the Department of Anatomy, LMU Munich before starting residency at LMU Munich in 2004. He underwent research fellowships between 2007-2008 at Wake Forest University, NC (Prof. Karl-Erik Andersson) and at Lund University, Sweden (Prof. Petter Hedlund) in clinical pharmacology. His main clinical interests include treatment of prostate cancer in addition to his basic and clinical research activities focusing on lower urinary tract and erectile dysfunction. He is a fellow of the European Board of Urology (EBU), member of the Scientific Congress Office of the EAU, member of the EAU and German working group on male LUTS as well as member of the Urological Research Society (URS). He has published more than 280 articles in peer-reviewed journals, authored 15 book chapters and received multiple national and international awards for his basic and clinical research, among them the 2017 Crystal Matula Award.